Exchange: NASDAQ
Industry: Drugs - Generic
Last Trade: 4:00 PM ET 2/9/2012
Last 10 Quotes:
What's This?
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 0.55 | 0.43 | 27.91 |
| EPS, GAAP | 0.36 | 0.33 | 9.09 |
| Consensus Estimate | 0.51 | 0.42 | 21.43 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 1.96 | 1.61 | 21.74 |
| EPS, GAAP | 0.89 | 0.70 | 27.14 |
| Consensus Estimate | 1.85 | NA | NA |
| MYL | Industry Average | |
| P/E (TTM) | 25.80 | 45.90 |
| P/E (Forward) | 9.61 | 14.20 |
| PEG Ratio | 0.90 | 0.72 |
| Price/Sales | 1.64 | 2.26 |
| Beta | 0.84 | 0.85 |
| 1:57 PM | 2/9/2012 | UPDATE: US Appeals Court Upholds Dismissal Of Some AstraZeneca Crestor Patent Suits |
| 12:31 PM | 2/9/2012 | US Appeals Court Upholds Dismissal Of Some AstraZeneca Crestor Patent Lawsuits |
| 2/9/2012 | The Score on Scoring: Mylan 1, Warner Chilcott 0 (WSJ.com) |
| 1/30/2012 | Top Analyst Upgrades & Downgrades (AAP, AZO, BAC, C, HFC, IMGN, JAKK, JPM, K, KEG, MEOH, MNST, MS, MYL, SPLS, TWX, WFM) (24/7 Wall St) |
| 1/19/2012 | These two metrics can tell you a lot. (The Motley Fool) |
| 12/30/2011 | 2012 Newest Biotech Trend (The Motley Fool) |
| 12/27/2011 | Break it down with the DuPont formula. (The Motley Fool) |
| 12/23/2011 | Biosimilar development partnerships are popping up everywhere. (The Motley Fool) |
| 12/7/2011 | Are these stocks ready to take on the market in a rubber match? (The Motley Fool) |
| 12/1/2011 | Ranbaxy Wins FDA Approval for Generic Lipitor (Barrons.com) |
![[sm0212smart]](http://s.wsj.net/public/resources/images/PF-AB863_sm0212_C_20120118122431.jpg)
![[smfineprint]](http://s.wsj.net/public/resources/images/PF-AB821_smfine_C_20120111122044.jpg)
![[sm0212funds]](http://s.wsj.net/public/resources/images/PF-AB839_sm0212_C_20120113140400.jpg)
![[sm0212ten]](http://s.wsj.net/public/resources/images/PF-AB840_sm0212_C_20120117120334.jpg)
